Patient support through Alnylam Assist®
The Alnylam Assist® resources on this page are here to help your patients with
primary hyperoxaluria type 1 (PH1).
Here to help your patients
Alnylam Assist® offers personalized support for patients being treated with OXLUMO™ (lumasiran). If you would like to access OXLUMO for one of your patients, the first step is completing the Start Form.
Electronic Start Form
Fill out the Electronic Start Form online with your patient.
Downloadable Start Form
Print the Start Form, complete it with your patient, then fax it to 1-833-256-2747.
What happens next?
- A Case Manager will reach out to either you or your patient within 1-2 business days of receiving the completed Start Form.
- The Alnylam Assist® team will help your patient access OXLUMO.
Alnylam Assist® offers comprehensive support for your patients throughout the treatment journey:
Benefits verification Help determining patient-specific coverage. Within 1-2 days, a summary of benefits will be communicated to you and your patient
Financial assistance Information about patient eligibility for financial assistance, such as our Commercial Copay Program, Patient Assistance Program for uninsured patients, and more*
Patient educationDisease education and product information for patients and their families through trained Patient Education Liaisons (PELs)
Reimbursement educationAn Alnylam Field Reimbursement Director is available to provide education about billing, coding, and the reimbursement process for OXLUMO to physicians and their office staff.
Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.
Patient advocacy organizations
Help your patient expand their network and stay informed by connecting them with independent patient advocacy organizations.
We hope you find the resources mentioned here helpful. Alnylam Pharmaceuticals is not affiliated with any of these organizations. By listing these resources, Alnylam Pharmaceuticals is not endorsing any particular service or group, and we are not responsible for the content of these sites or services. They are provided for informational purposes and should not replace a doctor’s medical advice.